Biotec Pharmacon presents its cancer program at ECCP in Toulouse
(Thomson Reuters ONE) - (Oslo, 3 September, 2009) Biotec Pharmacon on 4 September presentsits clinical program with SBG for cancer at the ECCP conference, ajoint meeting between Oslo Cancer Cluster and ToulouseCancer-Bio-Sante in France. Biotec Pharmacon will focus on the immunestimulating effects of the bioactive substance SBG and monoclonalantibodies (mAb) on different forms of cancer. The company will alsopresent its program with SBG for prevention and treatment of oralmucositis, a common and potentially serious side-effect of radiotherapy for head and neck cancer.The company is nearing completion of its first clinical phase IIIstudy with SBG for oral mucositis (severe ulcers in the mouth),whereas the immune therapy of cancer studies are in the final stageof phase I/II. In these studies SBG is being used in combinationtreatments with monoclonal antibodies (mAb) for treatment ofneurobslastoma in children, for breast cancer and for non-Hodgkin'slymphoma. The first of these studies is being carried out at theMemorial Sloan-Kettering Cancer Centre in the US, and the other twoat Ullevål University Hospital and the Norwegian Radium Hospital,respectively.The conference in Toulouse is the first European Cancer ClusterPartnering event, and seeks to strengthen the relationships betweenyoung and innovative companies in the field of cancer and potentialpartners within the international biopharmaceutical industry and inthe investment community. The companies presenting on the ECCP coverdifferent fields within oncology, such as diagnostics, therapies anddrug delivery.Biotec Pharmacon is a member of Oslo Cancer Cluster. The companywarmly supports initiatives like the ECCP, which can become a driverfor the development of new products that can improve the ways wefind, prevent and treat different forms of cancer.The strategic co-operation between Oslo Cancer Cluster, ToulouseCancèropole and Cancer-Bio-Santè Cluster was initiated in Novemberlast year, with an aim to become the leading cancer centres in Europefor developing new cancer therapies.For further information, please contact:CEO Lars Viksmoen, tel: +47 40 62 08 70Vice President, Business Development, Sven Rohmann, tel: +41 79 5778895The presentation will be made available on www.biotec.no on Friday 4September. Please also visit www.oslocancercluster.noAbout Biotec Pharmacon:The biopharmaceutical company Biotec Pharmacon developspharmaceutical products for prevention and treatment of immunerelated diseases. The company has developed the bioactive substanceSBG (soluble beta glucan), which is in clinical phase III for twoindications; treatment of diabetic ulcers and prevention andtreatment of oral mucositis. The company's clinical developmentprogram also includes immune therapy of cancer, where combinationtreatments with SBG and monoclonal antibodies are being studied inclinical phase I/II. In addition, the company is involved in severalpreclinical studies with SBG. Biotec Pharmacon also produces andmarkets non-pharmaceutical health- and diagnostic products and owns100% of Immunocorp Consumer Health AS and the marine enzyme companyBiotec Marine Biochemicals AS.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 03.09.2009 - 09:23 Uhr
Sprache: Deutsch
News-ID 5447
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotec Pharmacon presents its cancer program at ECCP in Toulouse"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
